Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June GlobeNewswire - Wed May 27, 3:05PM CDT

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 15.88 (+2.06%)
Relay Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire - Wed May 20, 7:21PM CDT

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 15.88 (+2.06%)
Relay Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue May 19, 3:03PM CDT

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 15.88 (+2.06%)
Business chart with glowing arrows and world map by Golden Dayz via Shutterstock
Rising Bond Yields Weigh on Stocks Barchart - Tue May 19, 10:21AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is down -0.68%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.95%. June E-mini S&P futures...

ALK : 49.26 (+2.05%)
SNDK : 2,184.75 (+11.54%)
HL : 15.96 (-0.62%)
CDE : 17.51 (-0.11%)
ADI : 434.46 (+4.83%)
STUB : 11.68 (+2.46%)
CRWV : 117.95 (+2.38%)
STX : 1,070.23 (+0.39%)
WDC : 746.23 (+4.79%)
AMD : 537.37 (+4.86%)
SCCO : 192.93 (+0.65%)
SPY : 746.74 (+1.04%)
Down market by Artit Wongpradu via Shutterstock
Stocks Pressured by Tech Weakness and Rising Bond Yields Barchart - Tue May 19, 9:13AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is down -0.35%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.45%. June E-mini S&P futures...

ALK : 49.26 (+2.05%)
ADI : 434.46 (+4.83%)
STUB : 11.68 (+2.46%)
CRWV : 117.95 (+2.38%)
STX : 1,070.23 (+0.39%)
WDC : 746.23 (+4.79%)
AMD : 537.37 (+4.86%)
SPY : 746.74 (+1.04%)
ADSK : 193.82 (+0.39%)
AAL : 15.99 (+3.70%)
QQQ : 740.62 (+2.51%)
TOL : 155.67 (+4.02%)
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies GlobeNewswire - Tue May 19, 5:00AM CDT

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported...

RLAY : 15.88 (+2.06%)
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates GlobeNewswire - Tue May 5, 3:05PM CDT

FDA Breakthrough Therapy designation granted to  zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib...

RLAY : 15.88 (+2.06%)
Relay Therapeutics Reports While the Market Decides What Zovegalisib Really Means Barchart - Mon May 4, 4:26PM CDT

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 4, 2026 Current Price $13.09 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 15.88 (+2.06%)
Relay Therapeutics Reports While Street Waits for Vascular Anomaly Data to Materialize Barchart - Fri May 1, 4:12PM CDT

Barchart Research What to Expect from RLAY Earnings RLAY Generated May 1, 2026 Current Price $12.72 EPS Estimate $$-0.35 Consensus Rating Strong Buy Average Move 6.98% Relay Therapeutics Reports While...

RLAY : 15.88 (+2.06%)
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 GlobeNewswire - Wed Apr 29, 3:05PM CDT

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 15.88 (+2.06%)

Barchart Exclusives

Microsoft vs. Nvidia: Which AI Giant Is the Better Dividend Stock for the Long Haul? Barchart - Fri Jun 19, 6:00PM CDT
Microsoft and NVIDIA are AI giants, but which stock is the better buy? Compare growth, valuation, dividends, and Wall Street ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.